Sector Alpha Week of 2026-07-29
Sector Alpha — machine-written from the numbers · Data as of 2026-07-29

Cronos Group Inc.

CRON
Healthcare · Drug Manufacturers - Specialty & Generic

Cronos Group Inc.'s price has outrun its earnings. +39.0% in a year against EPS −118.2% — the market is paying now for delivery later.

The sharpest disagreement: the price moved +39.0% in a year while annual EPS moved −118.2% — the difference is re-rating, and re-rating has to be repaid with earnings.

The price is between stages while the P/E sits at the 98th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +100.0% year on year. What settles it: whether earnings grow into a price that has already moved.

Price
$2.9
+39.0% 1Y
P/E
570.0×
98th pctile
of its own 1-year range
Revenue (Mar 26)
$0.1 B
+66.7% YoY
Profit (Mar 26)
$0.0 B
+100.0% YoY
Operating margin
0.0%
flat YoY
ROE
1%
FY25
ROIC
−4.7%
vs WACC 11.0% → −15.7 pp
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Cronos Group Inc. trades at $2.9, between stages. That is +8.0% against its own 200-day average. It sits at 57% of a 52-week range of $2 to $3. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 2 straight weeks.

Today the stock is between stages. At $2.9 it trades +8.0% versus its 200-day average and sits at 57% of its 52-week range ($2–$3).

Jul 26: $2.9 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 1-year window.
+8.0% versus the 200-day line, week — of stage —
Price50-day avg200-day avg
$3.4$3.0$2.6$2.2$1.8$$3$3Jul 25Oct 25Jan 26Apr 26Jul 26
$3.4$3.0$2.6$2.2$1.8$$3$3Jul 25Jan 26Jul 26
Beating or trailing, week by week since 2025 Each cell is one week from 2025 to now (56 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 25Jul 26

Against the market, two honest reads. Cumulative: over the last 1.0 years the stock moved +36% while the S&P 500 moved +19% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 98th percentile of its own range.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Cronos Group Inc. trades at 570.0× P/E, about the priciest it has ever traded. Its long-run median P/E is 40.6×, measured across 1.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 570.0× is about the priciest it has ever traded, against a long-run median of 40.6× measured over 1.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 570.0× vs a 40.6× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 1.0-year window; loss-period spikes above 122× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
about the priciest it has ever traded
P/EMedianEPS (TTM) (quarterly)
129.6×$0.11101.2×$0.0872.8×$0.0544.3×$0.0315.9×$0.00×$121.80×$0Jul 25Oct 25Jan 26Apr 26Jul 26
129.6×$0.11101.2×$0.0872.8×$0.0544.3×$0.0315.9×$0.00×$121.80×$0Jul 25Jan 26Jul 26
P/E
570.0×
98th percentile of 1y
PEG
n/m
not derivable — 3-year earnings growth unavailable

🚨 Why the multiple sits where it does: over the past year annual EPS moved −118.2% against a +39.0% price move — the price outran earnings, pushing the multiple UP its own range.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Cronos Group Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.

Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Where the trailing-twelve-month history is short, the curve falls back to single-quarter year-on-year growth — noisier, and the classifier smooths and caps base-effect spikes before reading. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from
RevenueProfitEPS
56%225%35%134%15%43%−5.3%−49%−26%−140%%%33.3%100%−96%Jun 23Sep 24Mar 26
56%225%35%134%15%43%−5.3%−49%−26%−140%%%33.3%100%−96%Jun 23Sep 24Mar 26
ROE Annual readings — the quarterly balance-sheet pieces this curve needs are not held for this stock, so the returns read moves once a year and carries less weight in the call.
the return curve, annual readings
ROE
5.1%−0.3%−5.7%−11%−16%%0%FY22FY23FY25
5.1%−0.3%−5.7%−11%−16%%0%FY22FY23FY25
Revenue growth
Rising
latest +33.3% · span −20.0% to +50.0%
ROE
Stuck low
latest 0.0% · span −14.9%–3.6%

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Growth, year by year: revenue +25.0% in FY25, profit −100.0% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
54%−99%40%−104%25%−109%11%−114%−4.0%−120%%%25%−100%FY21FY23FY25
54%−99%40%−104%25%−109%11%−114%−4.0%−120%%%25%−100%FY21FY23FY25
TTM growth by quarter Trailing-twelve-month growth versus the year-ago TTM, per quarter, %: revenue (left axis); profit and EPS (right axis). The acceleration read compares the last 4 quarters (+33.3%) with the last 8 annualized (+33.3%).
revenue stabilising
Revenue TTM YoYProfit TTM YoYEPS TTM YoY
56%−77%35%−87%15%−97%−5.3%−107%−26%−117%%%33.3%−80%Jun 23Sep 24Mar 26
56%−77%35%−87%15%−97%−5.3%−107%−26%−117%%%33.3%−80%Jun 23Sep 24Mar 26
Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+25.0%+18.6%
Stock price+39.0%
Revenue YoY (Mar 26)
+66.7%
latest quarter vs a year ago
Profit YoY (Mar 26)
+100.0%
latest quarter vs a year ago
Revenue 10y
25.7%
long-run compound pace

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

04 · 4-Factor Sector Score

4-Factor Sector Score

No sector-relative score — Cronos Group Inc. is not among the largest members shown in this industry comparison for Drug Manufacturers - Specialty & Generic.

The score is a rank WITHIN a peer set: every metric is scored by percentile against the other members. Without the peer set there is no score to state, so none is invented here.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Cronos Group Inc. reported $0.1 B of revenue in the Mar 26 quarter, +66.7% year on year. That is the 3rd straight quarter of year-on-year growth. Over 4 years it has compounded at 25.7% a year. The last full year, FY25, came in at $0.1 B. The last four reported quarters add to $0.2 B.

Cronos Group Inc. reported $0.1 B of revenue in the Mar 26 quarter, +66.7% year on year. That is the 3rd straight quarter of year-on-year growth. Over 4 years it has compounded at 25.7% a year. The last full year, FY25, came in at $0.1 B. The last four reported quarters add to $0.2 B.

FY25 revenue came in at $0.1 B (+25.0% on the year), capping 4 years at 25.7% compound. The latest quarter (Mar 26) printed $0.1 B, +66.7% year on year — the 3rd consecutive quarter of year-over-year growth.

FY25 revenue $0.1 B (+25.0% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
25.7% a year over 4 years
RevenueYoY growth
0.1654%0.1240%0.0825%0.0411%0.00−4.0%$ B%$0B25%FY21FY23FY25
0.1654%0.1240%0.0825%0.0411%0.00−4.0%$ B%$0B25%FY21FY23FY25
Mar 26: $0.1 B (+66.7% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
3rd straight quarter of growth
Revenue (quarterly)YoY growth
0.0572%0.0453%0.0333%0.0114%0.00−5.3%$ B%$0B66.7%Jun 23Sep 24Mar 26
0.0572%0.0453%0.0333%0.0114%0.00−5.3%$ B%$0B66.7%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +33.3% growth against the decade's 25.7% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +33.3% over the last 4 quarters against +33.3%/yr over the last 8 — stabilising.

→ Revenue grew — did margins hold as it scaled? Next: 0.0% this quarter (+0.0 pp YoY).

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Cronos Group Inc.'s operating margin is 0.0% in the Mar 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −500.0% to −13.3%. The current quarter is running above every full year in that window.

Cronos Group Inc.'s operating margin is 0.0% in the Mar 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −500.0% to −13.3%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 0.0%, +0.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −500.0%–−13.3%.

Why the margin moved: operating margin went +0.0 pp year on year while gross margin went +6.7 pp — the gain came mostly from the gross line: input costs and pricing.

FY25: −13.3% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a −500.0–−13.3% band over 5 years
operating marginYoY change (pp)
26%406%−116%303%−257%200%−398%97%−539%−6.2%%%−13.3%53.4%FY21FY23FY25
26%406%−116%303%−257%200%−398%97%−539%−6.2%%%−13.3%53.4%FY21FY23FY25
Mar 26: 0.0% operating margin (+0.0 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
8.0%108%−21%79%−50%50%−79%21%−108%−8.0%%%0%0%Jun 23Sep 24Mar 26
8.0%108%−21%79%−50%50%−79%21%−108%−8.0%%%0%0%Jun 23Sep 24Mar 26

→ Margins held — did that reach the bottom line? Next: profit +100.0% in the latest quarter.

07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Cronos Group Inc. earned $0.0 B of net profit in the Mar 26 quarter, +100.0% year on year. Full-year FY25 profit was $0.0 B. That is 40.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 4 of the last 12 reported quarters were loss-making.

Cronos Group Inc. earned $0.0 B of net profit in the Mar 26 quarter, +100.0% year on year. Full-year FY25 profit was $0.0 B. That is 40.0% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 4 of the last 12 reported quarters were loss-making.

Mar 26 profit was $0.0 B, +100.0% year on year. On the full year, FY25 printed $0.0 B (−100.0%).

FY25 profit $0.0 B (−100.0% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profitYoY growth
0.1−98.8%−0.1−99.4%−0.2−100.0%−0.3−100.6%−0.4−101.2%$ B%$0B−100%FY21FY23FY25
0.1−98.8%−0.1−99.4%−0.2−100.0%−0.3−100.6%−0.4−101.2%$ B%$0B−100%FY21FY23FY25
Mar 26: $0.0 B (+100.0% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
0.05224%0.02137%0.0050%−0.03−37%−0.06−124%$ B%$0B100%Jun 23Sep 24Mar 26
0.05224%0.02137%0.0050%−0.03−37%−0.06−124%$ B%$0B100%Jun 23Sep 24Mar 26

Why profit moved: revenue contributed +66.7% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +66.7% vs revenue +33.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.

→ Profit rose — but did the cash follow?

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Cronos Group Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $0.0 B of operating cash against $0.0 B of profit. After $0.0 B of capital spending, $0.0 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.

FY25: operating cash of $0.0 B against reported profit of $0.0 B, leaving free cash of $0.0 B after $0.0 B of capital spending.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $0.0 B vs profit $0.0 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
Operating cashNet profitFree cash
0.1−0.1−0.2−0.3−0.4$ B$0B$0B$0BFY21FY23FY25
0.1−0.1−0.2−0.3−0.4$ B$0B$0B$0BFY21FY23FY25
Mar 26: operating cash $0.0 B = 50% of the quarter's profit Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
0.022108%0.01479%0.00550%−0.00421%−0.012−8.0%$ B%$0B50%Jun 23Sep 24Mar 26
0.022108%0.01479%0.00550%−0.00421%−0.012−8.0%$ B%$0B50%Jun 23Sep 24Mar 26

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

→ So follow the cash to where it goes. Next: $0.0 B of building over 3 years.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Cronos Group Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

FY25: capex $0.0 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.0320.0240.0160.0080.000$ B$0BFY21FY23FY25
0.0320.0240.0160.0080.000$ B$0BFY21FY23FY25
Mar 26: capex $0.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.0220.020.0160.010.0110.000.005−0.010.000−0.02$ B$ B$0B$0BJun 23Sep 24Mar 26
0.0220.020.0160.010.0110.000.005−0.010.000−0.02$ B$ B$0B$0BJun 23Sep 24Mar 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROE is 1% and the ROIC − WACC spread is −15.7 pp.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Cronos Group Inc. earns a ROE of 0% in FY25. That is up from a trough of −30% in FY21. Return on invested capital clears the cost of that capital by −15.7 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 0.0% net margin on 0.13× asset turns.

FY25 ROE is 0%, recovered from a FY21 trough of −30% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY25): 0.0% net margin × 0.13× asset turns × 1.05× balance-sheet leverage ≈ 0.0% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: −4.7% − 11.0% = a −15.7 pp spread. The 11.0% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

FY25: ROE 0% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 11.0% cost of capital used on this page.
the climb back from FY21's −30%
ROEROIC (annual)WACC
18%−7.9%−34%−60%−86%%0%−1.1%FY21FY23FY25
18%−7.9%−34%−60%−86%%0%−1.1%FY21FY23FY25
Dec 25: ROIC −0.1% (TTM) vs WACC 11.0% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
14%4.0%−5.7%−15%−25%%−0.1%1.8%Jun 23Sep 24Mar 26
14%4.0%−5.7%−15%−25%%−0.1%1.8%Jun 23Sep 24Mar 26

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is not in our numbers.

11 · Dividend

Dividend

Cronos Group Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Cronos Group Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

→ No payout to follow. The cash question becomes what the business does with what it earns instead.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Cronos Group Inc. carries total debt of $0.0 B against shareholder equity of null as of Mar 26, a debt-to-equity of null. On the annual view that ratio went from 0.01 in FY21 to 0.00 in FY25. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of $0.0 B against shareholder equity of null — a debt-to-equity of null. On the annual view, debt-to-equity went from 0.01 (FY21) to 0.00 (FY25). Read the returns on this page with that leverage in mind.

FY25: debt $0.0 B at 0.00× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
0.0110.011×0.0080.008×0.0050.005×0.0030.002×0.000−0.001×$ B×$0B0.00×FY21FY23FY25
0.0110.011×0.0080.008×0.0050.005×0.0030.002×0.000−0.001×$ B×$0B0.00×FY21FY23FY25
Mar 26: debt $0.0 B, debt-to-equity null Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
1.21.2×0.60.6×0.00.0×−0.6−0.6×−1.2−1.2×$ B×$0B0.00×Jun 23Sep 24Mar 26
1.21.2×0.60.6×0.00.0×−0.6−0.6×−1.2−1.2×$ B×$0B0.00×Jun 23Sep 24Mar 26

→ Who owns this, and are they adding or leaving? Next: short interest is 1.8% of the float.

13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

1.8% of Cronos Group Inc.'s tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 3.9 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 1.8% of the float is sold short, and at typical trading volumes it would take about 3.9 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
1.8%
of the tradable float
Days to cover
3.9
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Cronos Group Inc.: the Z-score reads 12.79. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 12.79 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 12.79.

Related companies · same industry · Drug Manufacturers - Specialty & Generic Every company is compared on the shape of its own curves, not static ratios. The Revenue, EPS and ROCE columns each draw that company's last 12 quarters as a mini line of the ACTUAL level (trailing-twelve-month revenue and EPS, and the ROCE itself) — so a line that climbs is a business getting bigger, a line that sinks is one shrinking. The colour tracks the same line: green when it is rising or steadily healthy, amber when it is rolling over from a high (still elevated but turning down), red when it is falling, grey when flat or stuck. Colour and direction always agree — a green line never points down. The ROCE curve is the return on capital (annual readings for peers, so a slightly coarser line than the quarterly one at the top of this page). The Stage column then runs the same 12-quarter trajectory classifier used at the top of the page on each company and names where it sits. What lands a company in each bucket: CONSISTENT — growth stays positive across the window and returns are healthy (ROCE ≥ 15%, or ROE ≥ 12% for lenders); IMPROVING — profit or EPS fell into real decline, bottomed a few quarters back, and has climbed back to positive and held there; TURNING AROUND — the same kind of trough but more recent, with the latest quarters just lifting off it (an early, unconfirmed turn); TOPPING OUT — growth is still positive but decelerating hard from its own peak while returns have stopped rising; DETERIORATING — two or more growth curves are shrinking (latest below zero) and staying there, not one soft quarter; MIXED — the curves genuinely disagree, or no clean majority, so no single word fits; NO READ — fewer than eight usable quarters. It is a like-for-like read of every company against its own past, not a ranking against the group.
CompanyP/EMkt capRevenueEPSROCEStage
Cronos Group Inc. this page570.0×$1BNo read
Takeda Pharmaceutical Company Limited$56BTurning around
Haleon plc19.9×$45BMixed
Teva Pharmaceutical Industries Limited23.6×$37BNo read
Zoetis Inc.12.7×$32BConsistent
United Therapeutics Corporation19.3×$22BMixed
Viatris Inc.$21BMixed
Neurocrine Biosciences, Inc.28.1×$18BMixed
Elanco Animal Health Incorporated$13BNo read
Dr. Reddy's Laboratories Limited28.3×$10BMixed
Alkermes plc130.1×$8BTopping out
Liquidia Corporation355.6×$8BNo read
Hims & Hers Health, Inc.$7BNo read
Lantheus Holdings, Inc.24.7×$7BImproving
Kiniksa Pharmaceuticals International, plc80.2×$6BNo read
Amneal Pharmaceuticals, Inc.50.6×$6BNo read
Indivior Pharmaceuticals, Inc.21.0×$5BMixed
Regencell Bioscience Holdings Limited$3B
Supernus Pharmaceuticals, Inc.$3BDeteriorating
BioCryst Pharmaceuticals, Inc.$2BNo read
Prestige Consumer Healthcare Inc.13.2×$2BDeteriorating
Amylyx Pharmaceuticals, Inc.$2BNo read
HUTCHMED (China) Limited4.4×$2BNo read
ANI Pharmaceuticals, Inc.20.8×$2BNo read
Bausch Health Companies Inc.$2BNo read
Trulieve Cannabis Corp.$2BNo read
Xeris Biopharma Holdings, Inc.128.5×$1BNo read
Phibro Animal Health Corporation15.6×$1BImproving
Harrow, Inc.$1BNo read
Perrigo Company plc$1BNo read
Eton Pharmaceuticals, Inc.$1BNo read
Collegium Pharmaceutical, Inc.21.9×$1BNo read
Alvotech$1BNo read
Pacira BioSciences, Inc.225.0×$1BNo read
BioAge Labs, Inc.$1B
Amphastar Pharmaceuticals, Inc.12.1×$1BDeteriorating
Esperion Therapeutics, Inc.$1BNo read
Evotec SE$1BNo read
Ironwood Pharmaceuticals, Inc.6.2×$1BMixed
Tilray Brands, Inc.$0BNo read
12 · Frequently asked questions

Frequently asked questions

What is Cronos Group Inc.'s stock price today?

Cronos Group Inc. trades at $2.9, +39.0% over the past year. The company is valued at $1.0 B. The stock sits at 57% of its 52-week range of $2–$3, +8.0% versus its 200-day average. Against the S&P 500 it has been ahead on a trailing-13-week view for 2 weeks. — as of 29 July 2026.

What were Cronos Group Inc.'s latest quarterly results?

Cronos Group Inc. reported revenue of $0.1 B and net profit of $0.0 B for the Mar 26 quarter. Revenue rose 66.7% and profit rose 100.0% year on year. Earnings per share were $0.04. The operating margin was 0.0%, 0.0 pp higher than a year earlier. — as of 29 July 2026.

What is Cronos Group Inc.'s revenue?

Cronos Group Inc. reported revenue of $0.1 B in the Mar 26 quarter, +66.7% year on year. For the full FY25 fiscal year, revenue was $0.1 B (+25.0%). Over the last 4 years revenue compounded at 25.7% a year. — as of 29 July 2026.

What is Cronos Group Inc.'s profit?

Cronos Group Inc. earned $0.0 B of net profit in the Mar 26 quarter, +100.0% year on year. Full-year FY25 profit was $0.0 B. The operating margin ran 0.0% in the latest quarter. — as of 29 July 2026.

What is Cronos Group Inc.'s market cap?

Cronos Group Inc.'s market capitalisation is $1.0 B at a stock price of $2.9. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 29 July 2026.

What is Cronos Group Inc.'s P/E ratio?

Cronos Group Inc. trades at a P/E of 570.0×, at the 98th percentile of its own 1-year range, against a long-run median of 40.6×. This is a comparison with the stock's own history, not a value call — as of 29 July 2026.

Does Cronos Group Inc. pay a dividend?

No — Cronos Group Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 29 July 2026.

Is Cronos Group Inc. overvalued?

On its own history, Cronos Group Inc. looks expensive against its own history: its P/E of 570.0× sits at the 98th percentile of its 1-year range (long-run median 40.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 29 July 2026.

Is Cronos Group Inc. growing?

Yes — Cronos Group Inc. is growing: latest-quarter revenue +66.7% year on year, profit +100.0%, and the margin +0.0 pp at 0.0%. The earnings engine currently reads: improving — as of 29 July 2026.

How is Cronos Group Inc. performing?

Cronos Group Inc.'s latest readings are below. Its latest quarter's revenue rose 66.7% and profit rose 100.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 29 July 2026.

Is Cronos Group Inc. beating the market?

On recent form, yes — Cronos Group Inc. has been ahead of the S&P 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.0 years the stock moved +36% against the S&P 500's +19% — ahead of the index over the full window. — as of 29 July 2026.

Will Cronos Group Inc.'s stock price go up?

This page publishes no price forecast for Cronos Group Inc. What it measures instead: the stock price is $2.9. Its P/E of 570.0× sits at the 98th percentile of its own 1-year range. Direction is not something this site claims to know. — as of 29 July 2026.

Is the market betting against Cronos Group Inc.?

No — short interest is 1.8% of Cronos Group Inc.'s tradable float, about 3.9 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 29 July 2026.

What is Cronos Group Inc.'s capex?

Cronos Group Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 29 July 2026.

What is Cronos Group Inc.'s cash flow?

Cronos Group Inc. generated $0.0 B of operating cash flow in FY25 and $0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.0 B, so operating cash ran ahead of profit. — as of 29 July 2026.

How financially safe is Cronos Group Inc.?

On the balance sheet, the Z-score reads 12.79 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 29 July 2026.

Where is Cronos Group Inc. in its business cycle?

Cronos Group Inc.'s FY25 operating margin was −13.3%, against a 5-year band of −500.0%–−13.3%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 0.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 29 July 2026.

What could break the Cronos Group Inc. story?

The sharpest disagreement: the price moved +39.0% in a year while annual EPS moved −118.2% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 29 July 2026.

Is Cronos Group Inc. a stock worth studying right now?

This is not investment advice. The machine read: Cronos Group Inc.'s price has outrun its earnings. +39.0% in a year against EPS −118.2% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 29 July 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI